The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients.

Competing Interests: Disclosure LZ serves as a consultant for Merck and reports a grant from SEOM to study immune-related toxicities. TGN has been a consultant to and received fees from Parexel Imaging, Intrinsic Imaging, H3-Biomedicine, and AbbVie, outside of the current work. TGN also reports consultant fees from Bristol-Myers Squibb (BMS) for a Scientific Advisory Board focused on myocarditis related to immune checkpoint inhibitors and an unrestricted grant from AstraZeneca to study atherosclerosis related to immune checkpoint inhibitors. OR reports research support from Merck. Speaker for activities supported by educational grants from BMS and Merck. Consultant for Merck, Celgene, Five Prime, GlaxoSmithKline, Bayer, Roche/Genentech, Puretech, Imvax, Sobi. In addition, he has a patent ‘Methods of using pembrolizumab and trebananib’ pending. MJM has served as a consultant and/or received honorarium from AstraZeneca, Nektar Therapeutics, Catalysis Pharmaceuticals, Immunai. RJS has been a consultant/served on advisory boards for AstraZeneca, Eisai, Merck, Novartis, Oncosec, Pfizer, Replimune and received research funding from Merck. All other authors have declared no conflicts of interest.